Drugs Details

Drugs Info of Xyntha
Drugs Details
  • Drugs Type  : FDA
  • Date : 6th Jul 2015 07:26 am
  • Brand Name : Xyntha
  • Generic Name : Antihemophilic Factor (Recombinant), Plasma/Albumin-Free] For Intravenous Use, Freeze-Dried Powder
Descriptions

Antihemophilic Factor (Recombinant), Plasma/Albumin-Free, the active ingredient in XYNTHA, is a recombinant coagulation factor VIII produced by recombinant DNA technology for use in therapy of factor VIII deficiency. The Antihemophilic Factor (Recombinant), Plasma/Albumin-Free in XYNTHA (antihemophilic factor) is a purified glycoprotein with an approximate molecular mass of 170 kDa consisting of 1438 amino acids, which does not contain the B-domain.13 The amino acid sequence of Antihemophilic Factor (Recombinant), Plasma/Albumin-Free in XYNTHA (antihemophilic factor) is comparable to the 90 + 80 kDa form of human factor VIII.

The Antihemophilic Factor (Recombinant), Plasma/Albumin-Free in XYNTHA (antihemophilic factor) is secreted by a genetically engineered Chinese hamster ovary (CHO) cell line. The cell line is grown in a chemically defined cell culture medium that contains recombinant insulin, but does not contain any materials derived from human or animal sources. The Antihemophilic Factor (Recombinant), Plasma/Albumin-Free in XYNTHA (antihemophilic factor) is purified by a process that uses a series of chromatography steps, one of which is based on affinity chromatography using a patented synthetic peptide affinity ligand.14 The process also includes a solvent-detergent viral inactivation step and a virus-retaining nanofiltration step.

The potency expressed in International Units (IU) is determined using the chromogenic assay of the European Pharmacopoeia. The Wyeth manufacturing reference standard for potency has been calibrated against the World Health Organization (WHO) International Standard for factor VIII activity using the one-stage clotting assay. The specific activity of XYNTHA (antihemophilic factor) is 5500 to 9900 IU per milligram of protein.

XYNTHA (antihemophilic factor) is formulated as a sterile, nonpyrogenic, preservative-free, freeze-dried powder preparation for intravenous (IV) injection. Each single-use vial contains nominally 250, 500, 1000 or 2000 IU of XYNTHA (antihemophilic factor) . Upon reconstitution, the product is a clear to slightly opalescent, colorless solution that contains sodium chloride, sucrose, L-histidine, calcium chloride and polysorbate 80.

Indications

Control of Bleeding Episodes in Hemophilia A

XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).

XYNTHA (antihemophilic factor) does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease.

Surgical Prophylaxis in Patients with Hemophilia A

XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is indicated for surgical prophylaxis in patients with hemophilia A.

Dosage Administration

Treatment with XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free should be initiated under the supervision of a physician experienced in the treatment of hemophilia A.

Dosage and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient's clinical condition. Doses administered should be titrated to the patient's clinical response. In the presence of an inhibitor, higher doses may be required.1

One International Unit (IU) of factor VIII activity corresponds approximately to the quantity of factor VIII in one milliliter of normal human plasma. The calculation of the required dosage of factor VIII is based upon the empirical finding that, on average, 1 IU of factor VIII per kg body weight raises the plasma factor VIII activity by approximately 2 IU/dL.2 The required dosage is determined using the following formula:

Required units = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)

The labeled potency of XYNTHA (antihemophilic factor) is based on the European Pharmacopoeia chromogenic substrate assay, in which the Wyeth manufacturing standard has been calibrated using a one- stage clotting assay. This method of potency assignment is intended to harmonize XYNTHA (antihemophilic factor) with clinical monitoring using a one-stage clotting assay. [see CLINICAL PHARMACOLOGY]

Control of Bleeding Episodes

In the case of the following bleeding events, consideration should be given to maintaining the factor VIII activity at or above the plasma levels (in % of normal or in IU/dL) outlined below for the indicated period.

Type of Bleeding Episode Factor VIII
Level Required
(IU/dL or % of normal)
Frequency of Doses /
Duration of Therapy
Minor
Early hemarthrosis, minor muscle or oral bleeds.
20-40
Repeat every 12-24 hours as necessary until resolved. At least 1 day, depending upon the severity of the bleeding episode.
Moderate
Bleeding into muscles. Mild head trauma. Bleeding into the oral cavity.
30-60
Repeat infusion every 12-24 hours for 3-4 days or until adequate local hemostasis is achieved.
Major
Gastrointestinal bleeding. Intracranial, intra-abdominal or intrathoracic bleeding. Fractures.
60-100
Repeat infusion every 8-24 hours until bleeding is resolved.

Surgical Prophylaxis in Patients with Hemophilia A

In the case of the following bleeding events, consideration should be given to maintaining the factor VIII activity at or above the plasma levels (in % of normal or in IU/dL) outlined below for the indicated period. Monitoring of replacement therapy by means of plasma factor VIII activity is recommended, particularly for surgical intervention.

The following chart can be used to guide dosing in surgery:

Type of Bleeding Episode Factor VIII
Level Required
(IU/dL or % of normal)
Frequency of Doses /
Duration of Therapy
Minor
Minor operations, including tooth extraction.
30-60
Repeat infusion every 12-24 hours for 3-4 days or until adequate local hemostasis is achieved. For tooth extraction, a single infusion plus oral antifibrinolytic therapy within 1 hour may be sufficient.
Major
Major operations.
60-100
Repeat infusion every 8-24 hours until threat is resolved, or in the case of surgery, until adequate local hemostasis and wound healing are achieved.

Instructions for Use

XYNTHA (antihemophilic factor) is administered by intravenous (IV) infusion after reconstitution of the freeze-dried powder with the supplied pre-filled diluent (0.9% Sodium Chloride solution) syringe.

Patients should follow the specific reconstitution and administration procedures provided by their physicians. For instructions, patients should follow the recommendations in the FDA-Approved Patient Labeling . The procedures below are provided as general guidelines for the reconstitution and administration of XYNTHA (antihemophilic factor) .

Preparation and Reconstitution

Preparation
  1. Always wash your hands before performing the following procedures.
  2. Aseptic technique (meaning clean and germ-free) should be used during the reconstitution procedure.
  3. All components used in the reconstitution and administration of this product should be used as soon as possible after opening their sterile containers to minimize unnecessary exposure to the atmosphere.

Note: If you use more than one vial of XYNTHA (antihemophilic factor) per infusion, each vial should be reconstituted according to the following instructions. The diluent syringe should be removed, leaving the vial adapter in place, and a separate large luer lock syringe may be used to draw back the reconstituted contents of each vial. Do not detach the diluent syringes or the large luer lock syringe until you are ready to attach the large luer lock syringe to the next vial adapter.

Reconstitution
    1. Allow the vials of freeze-dried XYNTHA (antihemophilic factor) and the pre-filled diluent syringe to reach room temperature.
    2. Remove the plastic flip-top cap from the XYNTHA (antihemophilic factor) vial to expose the central portions of the rubber stopper.

 

Reconstitution - illustration 1
    1. Wipe the top of the vial with the alcohol swab provided, or use another antiseptic solution, and allow to dry. After cleaning, do not touch the rubber stopper with your hand or allow it to touch any surface.
    2. Peel back the cover from the clear plastic vial adapter package. Do not remove the adapter from the package.
    3. Place the vial on a flat surface. While holding the adapter package, place the vial adapter over the vial and press down firmly on the package until the adapter spike penetrates the vial stopper.

 

Reconstitution - illustration 2
    1. Grasp the plunger rod as shown in the diagram. Avoid contact with the shaft of the plunger rod. Attach the threaded end of the plunger rod to the diluent syringe plunger by pushing and turning firmly.

 

Reconstitution - illustration 3
    1. Break off the tamper-resistant plastic tip cap from the diluent syringe by snapping the perforation of the cap. Do not touch the inside of the cap or the syringe tip. The diluent syringe may need to be recapped (if not administering reconstituted XYNTHA (antihemophilic factor) immediately), so place the cap on its top on a clean surface in a spot where it would be least likely to become environmentally contaminated.

 

Reconstitution - illustration 4
    1. Lift the package away from the adapter and discard the package.

 

Reconstitution - illustration 5
    1. Place the vial on a flat surface. Connect the diluent syringe to the vial adapter by inserting the tip into the adapter opening while firmly pushing and turning the syringe clockwise until secured.

 

Reconstitution - illustration 6
    1. Slowly depress the plunger rod to inject all the diluent into the XYNTHA (antihemophilic factor) vial.

 

Reconstitution - illustration 7
    1. Without removing the syringe, gently swirl the contents of the vial until the powder is dissolved.
      Note: The final solution should be inspected visually for particulate matter before administration. The solution should be clear to slightly opalescent and colorless. If it is not, the solution should be discarded and a new kit should be used.
    2. Invert the vial and slowly draw the solution into the syringe.

 

Reconstitution - illustration 8
  1. Detach the syringe from the vial adapter by gently pulling and turning the syringe counter-clockwise. Discard the vial with the adapter attached.

Note: If the solution is not to be used immediately, the syringe cap should be carefully replaced. Do not touch the syringe tip or the inside of the cap.

The reconstituted solution may be stored at room temperature prior to administration, but should be administered within 3 hours.

XYNTHA (antihemophilic factor) , when reconstituted, contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of XYNTHA (antihemophilic factor) , including storage time elapsed in a PVC container following reconstitution. It is important that the recommendations in Dosage and Administration (2) be followed closely.

Administration

XYNTHA (antihemophilic factor) is administered by intravenous (IV) infusion after reconstitution with the supplied pre-filled diluent (0.9% Sodium Chloride solution, 4 mL) syringe. Parenteral drug products should be inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.

XYNTHA (antihemophilic factor) should be administered using the tubing provided in this kit and the pre-filled diluent syringe provided, or a single sterile disposable plastic syringe. In addition, the solution should be withdrawn from the vial using the vial adapter.

    1. Attach the syringe to the luer end of the infusion set tubing provided.
    2. Apply a tourniquet and prepare the injections site by wiping the skin well with an alcohol swab provided in the kit.

 

Administration - illustration 1
    1. Perform venipuncture. Insert the needle on the infusion set tubing into the vein, and remove the tourniquet. The reconstituted XYNTHA (antihemophilic factor) product should be injected intravenously over several minutes. The rate of administration should be determined by the patient's comfort level.

 

Administration - illustration 1

Reconstituted XYNTHA (antihemophilic factor) should not be administered in the same tubing or container with other medicinal products.3

Following completion of XYNTHA (antihemophilic factor) treatment, remove the infusion set and discard. Dispose of all unused solution, the empty vial(s), and the used needles and syringes in an appropriate container for throwing away waste that might hurt others if not handled properly.

How Supplied

Dosage Forms And Strengths

XYNTHA (antihemophilic factor) is supplied as a white to off-white powder in the following dosages:

  • 250 IU
  • 500 IU
  • 1000 IU
  • 2000 IU

XYNTHA™ Antihemophilic Factor (Recombinant), Plasma/Albumin-Free is supplied in kits that include single-use (Freeze-Dried) vials that contain nominally 250, 500, 1000, or 2000 IU per vial:

250 IU Kit: NDC 58394-012-01
500 IU Kit: NDC 58394-013-01
1000 IU Kit: NDC 58394-014-01
2000 IU Kit: NDC 58394-015-01

Actual factor VIII activity in IU is stated on the label of each XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free vial.

In addition, each XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free kit contains: one pre-filled diluent syringe containing 4 mL 0.9% Sodium Chloride with plunger rod for assembly, one vial adapter, one sterile infusion set, two alcohol swabs, one bandage, one gauze, and one package insert.

Storage and Handling

Product as packaged for sale: XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free should be stored under refrigeration at a temperature of 2° to 8°C (36° to 46°F). XYNTHA (antihemophilic factor) may also be stored at room temperature not to exceed 25°C (77°F) for up to 3 months, until the expiration date. The patient should write in the space provided on the outer carton the date the product was placed at room temperature. At the end of the 3-month period, the product should not be put back into the refrigerator, but should be used immediately or discarded. The diluent syringe may be stored at 2° to 25°C (36° to 77°F). Freezing should be avoided to prevent damage to the pre-filled diluent syringe. During storage, avoid prolonged exposure of XYNTHA (antihemophilic factor) vial to light. Do not use XYNTHA (antihemophilic factor) after the expiration date on the label.

Product after reconstitution: The reconstituted solution may be stored at room temperature prior to administration. The product does not contain a preservative and should be used within 3 hours.

Side Effects

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In Study 1, a pivotal phase 3 study, in which previously treated patients (PTPs) with hemophilia A received XYNTHA (antihemophilic factor) for routine prophylaxis and on-demand treatment, 94 subjects received at least one dose of XYNTHA (antihemophilic factor) , resulting in a total of 6775 infusions. [see Clinical Studies]

Study 2 is an on-going open-label, single-arm study of at least 25 evaluable PTPs with severe or moderately severe hemophilia A (factor VIII activity in plasma [FVIII:C] ≤ 2%) who require elective major surgery and are planned to receive XYNTHA (antihemophilic factor) replacement therapy for at least 6 days post-surgery. Twenty-two subjects received at least one dose of XYNTHA, resulting in 766 infusions. [see Clinical Studies]

In Study 1 (safety and efficacy study), the most frequently reported treatment-emergent adverse reaction was headache (24% of subjects). Other adverse reactions reported in ≥ 5% of subjects were: nausea (6%), diarrhea (5%), asthenia (5%) and pyrexia (5%). No subject developed anti- CHO or anti-TN8.2 antibodies.

In Study 2 (surgery study), the most frequently reported treatment-emergent adverse reaction was pyrexia (41% of subjects). Other adverse reactions reported in ≥ 5% of subjects were: headache (9%), nausea (9%), diarrhea (5%), vomiting (5%) and asthenia (5%). The adverse reactions reported in either study were considered mild or moderate in severity.

Immunogenicity is discussed below.

Immunogenicity

In Study 1, the incidence of FVIII inhibitors to XYNTHA (antihemophilic factor) was the primary safety endpoint. Two subjects with inhibitors were observed in 89 subjects (2.2%) who completed ≥ 50 exposure days. These results were consistent with the pre-specified endpoint that no more than 2 inhibitors may be observed in at least 81 subjects.

In a Bayesian statistical analysis, results from this study were used to update PTP results from a prior supporting study using XYNTHA (antihemophilic factor) manufactured at the initial facility, where one de novo and two recurrent inhibitors were observed in 110 subjects, and the experience with predecessor product (1 inhibitor in 113 subjects). This Bayesian analysis indicates that the population (true) inhibitor rate for XYNTHA (antihemophilic factor) , the estimate of the 95% upper limit of the true inhibitor rate, was 4.17% (see Table 1).

Table 1: Bayesian Posterior Distribution of Inhibitor Rate

View Enlarged Table

Interactions

None known.

Warnings

Included as part of the PRECAUTIONS section.

Precautions

Anaphylaxis and Severe Hypersensitivity Reactions

Allergic type hypersensitivity reactions are possible. Patients should be informed of the early signs or symptoms of hypersensitivity reactions [including hives (rash with itching), generalized urticaria, tightness of the chest, wheezing, and hypotension] and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physicians if these symptoms occur.

Neutralizing Antibodies

The occurrence of neutralizing antibodies (inhibitors) is well known in the treatment of patients with hemophilia A. Inhibitors have been detected in patients receiving factor VIII-containing products. Inhibitors are common in previously untreated patients4,5,6 and have been observed in previously treated patients on factor VIII products.7,8,9,10,11,12 Patients using coagulation factor VIII products, including XYNTHA (antihemophilic factor) , should be monitored for the development of factor VIII inhibitors. If expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an assay should be performed to determine if a factor VIII inhibitor is present. If detected, inhibitors should be titered in Bethesda Units (BU).

Formation of Antibodies to Hamster Protein

XYNTHA (antihemophilic factor) contains trace amounts of hamster proteins. Patients treated with this product could develop hypersensitivity to these non-human mammalian proteins.

Monitoring: Laboratory Tests

When clinically indicated, patients should have plasma factor VIII activity levels monitored by the one-stage clotting assay to confirm that adequate factor VIII levels have been achieved and are maintained. [see DOSAGE AND ADMINISTRATION]

It is recommended that individual factor VIII values for recovery and, if clinically indicated, other pharmacokinetic characteristics be used to guide dosing and administration.

Patient counseling Information

Allergic-type Hypersensitivity Reactions

Allergic-type hypersensitivity reactions are possible. Patients should be informed of the early signs of hypersensitivity reactions [including hives (rash with itching), generalized urticaria, tightness of the chest, wheezing, hypotension] and anaphylaxis. Patients should be advised to discontinue use of the product and contact their physicians if these symptoms occur.

Neutralizing Antibodies (Inhibitors)

Patients should be advised to contact their physician or treatment facility for further treatment and/or assessment, if they experience a lack of a clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor.

Pregnancy

Female patients should be advised to notify their physician if they become pregnant or intend to become pregnant during therapy.

Nursing

Patients should be advised to notify their physician if they are breastfeeding.

Usage While Traveling

Based on their current regimen, individuals with hemophilia using XYNTHA (antihemophilic factor) should be advised to bring an adequate supply of XYNTHA (antihemophilic factor) for anticipated treatment when traveling. Patients should be advised to consult with their healthcare professional prior to travel.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies have been conducted with XYNTHA (antihemophilic factor) to assess its mutagenic or carcinogenic potential. XYNTHA (antihemophilic factor) has been shown to be comparable to the predecessor product with respect to its biochemical and physicochemical properties, as well as its non-clinical in vivo pharmacology and toxicology. By inference, predecessor product and XYNTHA (antihemophilic factor) would be expected to have equivalent mutagenic and carcinogenic potential. The predecessor product has been shown to be nongenotoxic in the mouse micronucleus assay. No studies have been conducted in animals to assess impairment of fertility or fetal development.

Use In Specific Populations

Pregnancy

Pregnancy Category C

Animal reproduction studies have not been conducted with XYNTHA Antihemophilic Factor (Recombinant), Plasma/Albumin-Free. It is also not known whether XYNTHA (antihemophilic factor) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. XYNTHA (antihemophilic factor) should be given to a pregnant woman only if clinically indicated.

Labor and Delivery

There is no information available on the effect of factor VIII replacement therapy on labor and delivery.

Nursing Mothers

It is not known whether this drug is excreted into human milk. Because many drugs are excreted into human milk, caution should be exercised if XYNTHA (antihemophilic factor) is administered to nursing mothers.

OverDose

No symptoms of overdose have been reported.

ContrainDications

None.

Clinical Pharamacology

Mechanism of Action

Factor VIII is the specific clotting factor deficient in patients with hemophilia A (classical hemophilia).15 Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X.15 Activated factor X converts prothrombin into thrombin.15 Thrombin then converts fibrinogen into fibrin, and a clot is formed.15 Factor VIII activity is greatly reduced in patients with hemophilia A, and, therefore, replacement therapy is necessary. The administration of XYNTHA (antihemophilic factor) increases plasma levels of factor VIII activity and can temporarily correct the coagulation defect in these patients.

Pharmacodynamics

The administration of XYNTHA (antihemophilic factor) increases plasma levels of factor VIII activity and can temporarily correct the coagulation defect in hemophilia A patients.

Pharmacokinetics

In a pivotal crossover clinical study, 30 evaluable previously treated patients [PTP] ( ≥ 12 years) received a single infusion of 50 IU/kg of XYNTHA (antihemophilic factor) followed by a full-length recombinant FVIII (FLrFVIII, Advate®) or a single infusion of FLrFVIII followed by XYNTHA (antihemophilic factor) in a randomized crossover design. The one-stage clotting assay method was used to determine the concentrations of these two products in blood. XYNTHA (antihemophilic factor) was shown to be pharmacokinetically equivalent to FLrFVIII as the 90% confidence intervals for XYNTHA (antihemophilic factor) -to-FLrFVIII ratios of the mean values of Cmax and AUC were within pre-established limits of 80% to 125%. The pharmacokinetic parameters of XYNTHA (antihemophilic factor) in the above group of patients are summarized in Table 2.

In addition, 25 PTPs received a single infusion of 50 IU/kg of XYNTHA (antihemophilic factor) for a 6-month follow up PK study. The pharmacokinetic parameters were comparable between baseline and month 6 indicating no time-dependent changes in the pharmacokinetic properties of XYNTHA (antihemophilic factor) ; the 90% confidence intervals for XYNTHA (antihemophilic factor) 6 month-to-baseline ratios of the mean values of Cmax and AUC∞ were within pre-established limits of 80% to 125%.

Table 2: Pharmacokinetic Parameter Estimates for XYNTHA (antihemophilic factor) at Baseline (Cross-over phase) and Month 6 (Follow-up phase) in Previously Treated Patients with Hemophilia A

Parameter Parameters at Initial Visit
(Crossover phase, n = 30)
Mean ± SD
Parameters at Month 6
(Follow-up phase, n = 25)
Mean ± SD
Cmax (IU/mL) 1.08 ± 0.22 1.24 ± 0.42
AUC (IU·hr/mL) 13.5 ± 5.6 15.0 ± 7.5
t1/2 (hr) 11.2 ± 5.0 11.8 ± 6.2*
CL (mL/hr/kg) 4.51 ± 2.23 4.04 ± 1.87
K-value    
(IU/dL per IU/kg) In vivo Recovery (%) 2.15 0.44 103 ± 21 2.47 0.84 116 ± 40
Abbreviations: AUC = area under the plasma concentration-time curve from time zero to infinity; Cmax = peak concentration; K-value = incremental recovery; t1/2 = plasma elimination half-life; CL = clearance; n = number of subjects; SD = standard deviation.
* One subject was excluded from the calculation due to lack of a well-defined terminal phase.

Animal Toxicology and/or Pharmacology

Preclinical studies evaluating XYNTHA (antihemophilic factor) in hemophilia A dogs without inhibitors demonstrated safe and effective restoration of hemostasis. XYNTHA (antihemophilic factor) demonstrated a toxicological profile that was similar to the toxicological profile observed with the predecessor product. Toxicity associated with XYNTHA (antihemophilic factor) was primarily associated with anti-FVIII neutralizing antibody generation first detectable at 15 days of repeat dosing in high (approximately 735 IU/kg/day) level dosed non-human primates.

Clinical Studies

The efficacy of XYNTHA (antihemophilic factor) was evaluated in Study 1, in which subjects received XYNTHA (antihemophilic factor) on a prophylaxis treatment regimen, with on-demand treatment administered as clinically indicated. Ninety-four (94) subjects were enrolled and treated with at least one dose and all are included in the intent-to-treat (ITT) population. Eighty-nine (89) subjects accrued ≥ 50 exposure days. From the 94 subjects enrolled, thirty (30) evaluable subjects participated in the PK study and received at least 1 PK dose. Twenty-five (25) evaluable subjects with FVIII:C ≤ 1% completed both the first (PK1) and the second (PK2) assessments [see CLINICAL PHARMACOLOGY]. Median age for the 94 treated subjects was 24 years (mean 27.7 and range 12-60 years). All subjects had ≥ 150 previous exposure days with baseline FVIII activity level of ≤ 2%.

In the open-label safety and efficacy period, all 94 subjects received XYNTHA (antihemophilic factor) for routine prophylaxis at the dose of 30 ± 5 IU/kg 3 times a week with provisions for dose escalation based on pre-specified criteria. Seven (7) dose escalations were prescribed for 6 subjects during the course of the study. Forty-three (43) of ninety-four (94), i.e. 45.7%, subjects reported no bleeding while on routine prophylaxis. The median annualized bleeding rate (ABR) for all bleeding episodes was 1.9 (mean 3.9, range 0 to 42.1).

Fifty-three (53) of 94 subjects received XYNTHA (antihemophilic factor) for on-demand treatment for a total of 187 bleeding episodes (Table 3). Seven of these bleeding episodes occurred in subjects prior to switching to a prophylaxis treatment regimen. One hundred ten of one hundred eighty (110/180) bleeds (61.1%) occurred ≤ 48 hours after the last dose and 38.9% (70 of 180 bleeds) occurred > 48 hours after the last dose. The majority of bleeds reported to occur ≤ 48 hours after the last prophylaxis dose were traumatic (64 of 110 bleeds; 58.2%). Forty-two (42) of 70 bleeds (60%) reported to occur > 48 hours after the last prophylaxis dose were spontaneous. The on-demand treatment dosing regimen was determined by the investigator. The median dose for on-demand treatment was 30.6 IU/kg (range, 6.4 to 74.4 IU/kg).

Table 3: Time Interval Between Last Prophylaxis Dose of XYNTHA (antihemophilic factor) and Start of Bleed

View Enlarged Table

The majority of bleeding episodes (173/187; 92.5%) resolved with 1 or 2 infusions. Subjects rated the outcomes of infusions on a pre-specified four (4) point hemostatic efficacy scale. One hundred thirty-two (132) of 187 bleeding episodes (70.6%) treated with XYNTHA (antihemophilic factor) were rated excellent or good in their response to initial treatment, 45 (24.1%) were rated moderate. Five [5] (2.7%) were rated no response and 5 (2.7%) were not rated.

Table 4: Summary of Response to Infusions to Treat New Bleeding Episode by Number of Infusions Needed for Resolution

Response to 1st Infusion Number of Infusions (%) Total Number
of Bleeds
1 2 3 4 > 4
Excellent 42 (95.5) 2
(4.5)
0
(0.0)
0
(0.0)
0
(0.0)
44
Good 69 (78.4) 16 (18.2) 3
(3.4)
0
(0.0)
0
(0.0)
88
Moderate 24 (53.3) 16 (35.6) 2
(4.4)
0
(0.0)
3
(6.7)
45
No Response 0 (0.0) 0
(0.0)
2 (40.0) 2 (40.0) 1 (20.0) 5
Not Assessed 4 (80.0) 0 (0.0) 0
(0.0)
1 (20.0) 0
(0.0)
5a
Total 139 (74.3) 34 (18.2) 7
(3.7)
3
(1.6)
4
(2.1)
187
a Includes 1 infusion with commercial FVIII that occurred before routine prophylaxis began.

In an ongoing, open-label study of XYNTHA (antihemophilic factor) in surgical prophylaxis, 21 of at least 25 evaluable PTPs with severe or moderately severe (FVIII:C ≤ 2%) hemophilia A undergoing major surgical procedures received XYNTHA (antihemophilic factor) . One (1) subject received XYNTHA (antihemophilic factor) for a pre-surgery pharmacokinetic assessment only and had not undergone surgery.

The results of an interim analysis on 21 of the 25 planned evaluable subjects who had undergone major surgical procedures (13 total knee replacements, 1 hip replacement, 3 synovectomies, 1 left ulnar nerve transposition release, 1 ventral hernia repair/scar revision, 1 knee arthroscopy, 1 revision and debridement of the knee after a total knee replacement) are presented in Table 5. For the 21 surgical subjects, investigator's ratings of efficacy at the end of surgery and at the end of the initial postoperative period were excellent or good for all assessments. All reported blood loss during the intra-operative and postoperative periods was rated normal with the exception of one subject who experienced iatrogenic bleeding.

Table 5: Summary of Hemostatic Efficacy

Time of Hemostatic Efficacy Assessment Excellent Good Number of subjects
End of surgery 14 (67%) 7 (33%) 21
End of initial postoperative perioda 16 (84%) 3 (16%) 19
a Conclusion of initial postoperative period is date of discharge or postoperative Day 6, whichever occurs later.

Patient Information

XYNTHA™
(ZIN-tha)

[ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE]

Please read this Patient Information carefully before using XYNTHA (antihemophilic factor) and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical problems or your treatment.

What is XYNTHA (antihemophilic factor) ?

XYNTHA (antihemophilic factor) is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia A. Hemophilia A is also called classic hemophilia.

XYNTHA (antihemophilic factor) is not used to treat von Willebrand's Disease.

What should I tell my doctor before using XYNTHA (antihemophilic factor) ?

Tell your doctor about all of your medical conditions, including if you

  • are pregnant or planning to become pregnant. It is not known if XYNTHA (antihemophilic factor) may harm your unborn baby.
  • are breastfeeding. It is not known if XYNTHA (antihemophilic factor) passes into your milk and if it can harm your baby.

Tell you doctor and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines such as over-the-counter medicines, supplements, or herbal remedies.

How should I infuse XYNTHA (antihemophilic factor) ?

See the step-by-step instructions for infusing XYNTHA (antihemophilic factor) at the end of this leaflet. You should always follow the specific instructions given by your doctor. The steps listed below are general guidelines for using XYNTHA (antihemophilic factor) . If you are unsure of the procedures, please call your doctor or pharmacist before using.

Call your doctor right away if bleeding is not controlled after using XYNTHA (antihemophilic factor) .

Your doctor will prescribe the dose that you should take.

Your doctor may need to take blood tests from time to time.

Talk to your doctor before traveling. You should plan to bring enough XYNTHA (antihemophilic factor) for your treatment during this time.

What if I take too much XYNTHA (antihemophilic factor) ?

Call your doctor if you take too much XYNTHA (antihemophilic factor) .

What are the possible side effects of XYNTHA (antihemophilic factor) ?

Allergic reactions may occur with XYNTHA (antihemophilic factor) . Call your doctor or get emergency treatment right away if you have any of the following symptoms:

wheezing
difficulty breathing

chest tightness

turning blue (look at lips and gums)

fast heartbeat

swelling of the face

faintness

rash

hives

Your body can also make antibodies, called "inhibitors," against XYNTHA (antihemophilic factor) , which may stop XYNTHA (antihemophilic factor) from working properly.

Some common side effects of XYNTHA (antihemophilic factor) are headache, fever, nausea, vomiting, diarrhea, or weakness.

These are not all the possible side effects of XYNTHA (antihemophilic factor) .

Tell your doctor about any side effect that bothers you or that does not go away.

How should I store XYNTHA (antihemophilic factor) ?

Do not freeze XYNTHA (antihemophilic factor) .

Store XYNTHA (antihemophilic factor) in the refrigerator at 36° to 46°F (2° to 8°C). XYNTHA (antihemophilic factor) can last at room temperature (below 77°F) for up to 3 months. If you store XYNTHA (antihemophilic factor) at room temperature, be careful to write down the date you put XYNTHA (antihemophilic factor) at room temperature, so you will know when to throw it out. There is a space on the carton for you to write the date.

Throw away any unused XYNTHA (antihemophilic factor) after the expiration date.

After reconstituting XYNTHA (antihemophilic factor) , you can store it at room temperature for up to 3 hours. If you have not used it in 3 hours, throw it away.

Store the diluent syringe at 36° to 77°F (2° to 25°C).

Do not use reconstituted XYNTHA (antihemophilic factor) if it is not clear to slightly opalescent and colorless.

What else should I know about XYNTHA (antihemophilic factor) ?

Medicines are sometimes prescribed for purposes other than those listed here. Do not use XYNTHA (antihemophilic factor) for a condition for which it is not prescribed. Do not share XYNTHA (antihemophilic factor) with other people, even if they have the same symptoms that you have.

This leaflet summarizes the most important information about XYNTHA (antihemophilic factor) . If you would like more information, talk to your doctor. You can ask your doctor or pharmacist for information about XYNTHA (antihemophilic factor) that was written for healthcare professionals.

Instructions for Using XYNTHA (antihemophilic factor)

XYNTHA (antihemophilic factor) is supplied as a powder. Before it can be infused in your vein (intravenous injection), you must reconstitute the powder by mixing it with the liquid diluent supplied. The liquid diluent is 0.9% sodium chloride. XYNTHA (antihemophilic factor) should be reconstituted and infused using the infusion set, diluent, syringe, and adapter provided in this kit, and by following the directions below.

RECONSTITUTION

Always wash your hands before doing the following steps. Try to keep everything clean and germ-free while you are reconstituting XYNTHA (antihemophilic factor) . Once you open the vials, you should finish reconstituting XYNTHA (antihemophilic factor) as soon as possible. This will help to keep them germ-free.

Note: If you use more than one vial of XYNTHA (antihemophilic factor) for each infusion, reconstitute each vial according to steps 1 through 11.

    1. Let the vial of XYNTHA (antihemophilic factor) and the pre-filled diluent syringe reach room temperature.
    2. Remove the plastic flip-top cap from the XYNTHA (antihemophilic factor) vial to show the center part of the rubber stopper.

 

Reconstitution - illustration 1
    1. Wipe the top of the vial with the alcohol swab provided, or use another antiseptic solution, and allow to dry. After cleaning, do not touch the rubber stopper with your hand or allow it to touch any surface.
    2. Peel back the cover from the clear plastic vial adapter package. Do not remove the adapter from the package.
    3. Place the vial on a flat surface. While holding the adapter in the package, place the vial adapter over the vial. Press down firmly on the package until the adapter snaps into place on top of the vial, with the adapter spike going into the vial stopper.

 

Reconstitution - illustration 2
    1. Grasp the plunger rod as shown in the picture below. Do not touch the shaft of the plunger rod. Attach the threaded end of the plunger rod to the diluent syringe plunger by pushing and turning firmly.

 

Reconstitution - illustration 3
    1. Break off the tamper-resistant, plastic-tip cap from the diluent syringe by snapping the perforation of the cap. Do not touch the inside of the cap or the syringe tip. The diluent syringe may need to be recapped (if reconstituted XYNTHA (antihemophilic factor) is not used immediately), so place the cap on its top on a clean surface in a spot where it will stay clean.

 

Reconstitution - illustration 4
    1. Lift the package cover away from the adapter and discard the package.

 

Reconstitution - illustration 5
    1. Place the vial on a flat surface. Connect the diluent syringe to the vial adapter by inserting the tip of the syringe into the adapter opening while firmly pushing and turning the syringe clockwise until the connection is secured.

 

Reconstitution - illustration 6
    1. Slowly push the plunger rod to inject all the diluent into the XYNTHA (antihemophilic factor) vial.

 

Reconstitution - illustration 7
    1. With the syringe still connected to the adapter, gently swirl the contents of the vial until the powder is dissolved.

      Look at the final solution before infusing it. The solution should be clear to slightly opalescent and colorless. If it is not, throw away the solution and use a new kit.
    2. Make sure the syringe plunger rod is still fully pressed down, then turn over the vial. Slowly pull the solution into the syringe. Turn the syringe upward again and remove any air bubbles by gently tapping the syringe with your finger and slowly pushing air out of the syringe.

      If you reconstituted more than one vial of XYNTHA (antihemophilic factor) , remove the diluent syringe from the vial adapter and leave the vial adapter attached to the vial. Quickly attach a separate large luer lock syringe and pull the reconstituted solution as instructed above. Repeat this procedure with each vial in turn. Do not detach the diluent syringes or the large luer lock syringe until you are ready to attach the large luer lock syringe to the next vial adapter.

 

Reconstitution - illustration 8
  1. Remove the syringe from the vial adapter by gently pulling and turning the syringe counterclockwise. Throw away the vial with the adapter attached.

If you are not using the solution right away, you should carefully replace the syringe cap. Do not touch the syringe tip or the inside of the cap.

XYNTHA (antihemophilic factor) should be infused within 3 hours after reconstitution. The reconstituted solution may be stored at room temperature prior to infusion.

INFUSION (Intravenous Injection)

Your doctor or healthcare professional should teach you how to infuse XYNTHA (antihemophilic factor) . Once you learn how to self-infuse, you can follow the instructions in this insert.

    1. Attach the syringe to the luer end of the provided infusion set tubing.
    2. Apply a tourniquet and prepare the injection site by wiping the skin well with an alcohol swab provided in the kit.

 

Reconstitution - illustration 2
    1. Insert the butterfly needle of the infusion set tubing into your vein as instructed by your doctor or healthcare professional. Remove the tourniquet. Infuse the reconstituted XYNTHA (antihemophilic factor) product over several minutes. Your comfort level should determine the rate of infusion.

 

Reconstitution - illustration 2
  1. After infusing XYNTHA (antihemophilic factor) , remove the infusion set and discard. The amount of drug product left in the infusion set will not affect your treatment. Dispose of all unused solution, the empty vial(s), and the used needles and syringes in an appropriate container used for throwing away waste that might hurt others if not handled properly.

It is a good idea to record the lot number from the XYNTHA (antihemophilic factor) vial label every time you use XYNTHA (antihemophilic factor) . You can use the peel-off label found on the vial to record the lot number.

Consumer Overview Uses

No Information Available!

Consumer Overview Side Effect

No Information Available!

Consumer Overview Missed Dose

No Information Available!

Patient Detailed Side Effect

No Information Available!

Patient Detailed How Take

No Information Available!

Patient Detailed Avoid Taking

No Information Available!

Rx Scoops
Featured Topics
Advertisements
Copyrights ©2014: Rx Scoops - Designed & Developed By - GOIGI